Leukemia Clinical Trials in Philadelphia

Showing 901-920 of 1,502 trials

CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures

NCT02688855

The OL1000 is intended to be used as a non-invasive adjunctive treatment for adult males or females that have sustained a closed, unstable ankle fracture that requires surgical treatment for stabilization. The initiation of the adjunctive treatment is to begin within 11 days of surgical stabilization.

Bimalleolar Ankle Fractures

Encore Medical, L.P.217 participantsStarted Jan 2017

Tucson, Arizona, United States • Los Angeles, California, United States • Hollywood, Florida, United States +6 more locations

TERMINATEDPhase 4< 1 mile

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

NCT04195958

This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma. Exercise capacity will be assessed using cardiopulmonary exercise testing (CPET). Physical activity and sleep quality will be assessed with a wearable physical activity and sleep monitor. The study will consist of a 4-week screening period, a 24-week treatment period, and a 4-week safety follow-up. Approximately 60 participants will be enrolled, and omalizumab will be dosed according to the approved United States Package Insert (USPI) dosing table.

Moderate-to-severe Allergic Asthma

Genentech, Inc.3 participantsStarted Nov 2020

Rolling Hills Estates, California, United States • Denver, Colorado, United States • Pembroke Pines, Florida, United States +9 more locations

CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

Leukemia Trials in Other Cities

PEN-866 in Patients With Advanced Solid Malignancies

Safety Study of MGA271 in Refractory Cancer

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

KRT-232 and TKI Study in Chronic Myeloid Leukemia

Other Conditions in Philadelphia